FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3002263815> ?p ?o ?g. }

• W3002263815 endingPage "1405" @default.
• W3002263815 startingPage "1396" @default.
• W3002263815 abstract "Abstract Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to aid stratification to innovative treatment. Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLBCL patients. We analyzed the prognostic impact of TMTV and prognostic indices in DLBCL patients, aged 60 to 80 years, from the phase 3 REMARC study that randomized responding patients to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) into maintenance lenalidomide or placebo. TMTV was computed on baseline positron emission tomography/computed tomography using the 41% maximum standardized uptake value method; the optimal TMTV cutoff for progression-free (PFS) and overall survival (OS) was determined and confirmed by a training validation method. There were 301 out of 650 evaluable patients, including 192 patients classified as germinal center B-cell–like (GCB)/non-GCB and MYC/BCL2 expressor. Median baseline TMTV was 238 cm3; optimal TMTV cutoff was 220 cm3. Patients with high vs low TMTV showed worse/higher Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2, stage III or IV disease, &gt;1 extranodal site, elevated lactate dehydrogenase, International Prognostic Index (IPI) 3-5, and age-adjusted IPI 2-3. High vs low TMTV significantly impacted PFS and OS, independent of maintenance treatment. Although the GCB/non-GCB profile and MYC expression did not correlate with TMTV/survival, BCL2 &gt;70% impacted PFS and could be stratified by TMTV. Multivariate analysis identified baseline TMTV and ECOG PS as independently associated with PFS and OS. Even in responding patients, after R-CHOP, high baseline TMTV was a strong prognosticator of inferior PFS and OS. Moreover, TMTV combined with ECOG PS may identify an ultra-risk DLBCL population. This trial was registered at www.clinicaltrials.gov as #NCT01122472." @default.
• W3002263815 created "2020-01-30" @default.
• W3002263815 creator A5003078312 @default.
• W3002263815 creator A5003273516 @default.
• W3002263815 creator A5004897638 @default.
• W3002263815 creator A5006913531 @default.
• W3002263815 creator A5009487344 @default.
• W3002263815 creator A5010733763 @default.
• W3002263815 creator A5012900514 @default.
• W3002263815 creator A5014639728 @default.
• W3002263815 creator A5024022602 @default.
• W3002263815 creator A5025204567 @default.
• W3002263815 creator A5030703425 @default.
• W3002263815 creator A5032462496 @default.
• W3002263815 creator A5033073385 @default.
• W3002263815 creator A5051605599 @default.
• W3002263815 creator A5052452447 @default.
• W3002263815 creator A5055439790 @default.
• W3002263815 creator A5059641957 @default.
• W3002263815 creator A5062305482 @default.
• W3002263815 creator A5065987951 @default.
• W3002263815 creator A5067988271 @default.
• W3002263815 creator A5069409600 @default.
• W3002263815 creator A5072218217 @default.
• W3002263815 creator A5072246038 @default.
• W3002263815 creator A5076627885 @default.
• W3002263815 creator A5079749862 @default.
• W3002263815 creator A5082232325 @default.
• W3002263815 creator A5082805908 @default.
• W3002263815 creator A5086219277 @default.
• W3002263815 creator A5086354986 @default.
• W3002263815 creator A5090326578 @default.
• W3002263815 date "2020-04-16" @default.
• W3002263815 modified "2023-10-16" @default.
• W3002263815 title "High total metabolic tumor volume at baseline predicts survival independent of response to therapy" @default.
• W3002263815 cites W1597318419 @default.
• W3002263815 cites W1996764137 @default.
• W3002263815 cites W2063691874 @default.
• W3002263815 cites W2075627595 @default.
• W3002263815 cites W2088783247 @default.
• W3002263815 cites W2131900456 @default.
• W3002263815 cites W2133201432 @default.
• W3002263815 cites W2133650808 @default.
• W3002263815 cites W2135471715 @default.
• W3002263815 cites W2144329058 @default.
• W3002263815 cites W2158267770 @default.
• W3002263815 cites W2167556523 @default.
• W3002263815 cites W2172003817 @default.
• W3002263815 cites W2275941472 @default.
• W3002263815 cites W2291210741 @default.
• W3002263815 cites W2533964882 @default.
• W3002263815 cites W2566839935 @default.
• W3002263815 cites W2588651118 @default.
• W3002263815 cites W2605767476 @default.
• W3002263815 cites W2731741866 @default.
• W3002263815 cites W2784752532 @default.
• W3002263815 cites W2787594587 @default.
• W3002263815 cites W2788217422 @default.
• W3002263815 cites W2791448358 @default.
• W3002263815 cites W2795456460 @default.
• W3002263815 cites W2807205254 @default.
• W3002263815 cites W2887692520 @default.
• W3002263815 cites W2895040802 @default.
• W3002263815 cites W2927995861 @default.
• W3002263815 cites W2949514247 @default.
• W3002263815 cites W4205736005 @default.
• W3002263815 doi "https://doi.org/10.1182/blood.2019003526" @default.
• W3002263815 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7162688" @default.
• W3002263815 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31978225" @default.
• W3002263815 hasPublicationYear "2020" @default.
• W3002263815 type Work @default.
• W3002263815 sameAs 3002263815 @default.
• W3002263815 citedByCount "102" @default.
• W3002263815 countsByYear W30022638152020 @default.
• W3002263815 countsByYear W30022638152021 @default.
• W3002263815 countsByYear W30022638152022 @default.
• W3002263815 countsByYear W30022638152023 @default.
• W3002263815 crossrefType "journal-article" @default.
• W3002263815 hasAuthorship W3002263815A5003078312 @default.
• W3002263815 hasAuthorship W3002263815A5003273516 @default.
• W3002263815 hasAuthorship W3002263815A5004897638 @default.
• W3002263815 hasAuthorship W3002263815A5006913531 @default.
• W3002263815 hasAuthorship W3002263815A5009487344 @default.
• W3002263815 hasAuthorship W3002263815A5010733763 @default.
• W3002263815 hasAuthorship W3002263815A5012900514 @default.
• W3002263815 hasAuthorship W3002263815A5014639728 @default.
• W3002263815 hasAuthorship W3002263815A5024022602 @default.
• W3002263815 hasAuthorship W3002263815A5025204567 @default.
• W3002263815 hasAuthorship W3002263815A5030703425 @default.
• W3002263815 hasAuthorship W3002263815A5032462496 @default.
• W3002263815 hasAuthorship W3002263815A5033073385 @default.
• W3002263815 hasAuthorship W3002263815A5051605599 @default.
• W3002263815 hasAuthorship W3002263815A5052452447 @default.
• W3002263815 hasAuthorship W3002263815A5055439790 @default.
• W3002263815 hasAuthorship W3002263815A5059641957 @default.
• W3002263815 hasAuthorship W3002263815A5062305482 @default.
• W3002263815 hasAuthorship W3002263815A5065987951 @default.
• W3002263815 hasAuthorship W3002263815A5067988271 @default.

• next